At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 16 enrolled
Drug / intervention
abataceptbiological
Likely dose
abatacept 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Abatacept For The Treatment Of Primary Biliary Cirrhosis With An Incomplete Biochemical Response To Ursodeoxycholic Acid
In Brief
A Phase 4 clinical trial evaluating abatacept for Primary Biliary Cirrhosis. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if abatacept (Orencia) is effective in patients with primary biliary cirrhosis who do not respond adequately to standard treatment with ursodeoxycholic acid (UDCA, Urso, Ursodiol, Actigall).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Biliary Cirrhosis
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartSep 2014
Primary CompletionOct 2018
TodayJul 2026
First PostedMar 5, 2014
Enrollment StartSep 1, 2014
Primary CompletionOct 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.3 years ago
Interventions
abataceptbiological
125 mg subcutaneously each week for 24 weeks